COMPOSITIONS AND METHOD FOR TREATING COMPLEMENT-ASSOCIATED CONDITIONS
To provide methods for selecting and identifying a patient for treating with a factor D inhibitor.SOLUTION: Provided is a method of predicting progression rate of a degenerative disease in a patient having the degenerative disease, the method comprising: (a) determining the presence of at least one degenerative disease-associated polymorphism in a biological sample obtained from the patient by (i) providing a nucleic acid sample isolated from the biological sample, and (ii) detecting the genotype of the nucleic acid sample for the presence of at least one degenerative disease-associated polymorphism, the polymorphism being a risk allele selected from the group consisting of a CFI allele, a CFH allele, a C2 allele, a CFB allele, or a C3 allele; and (b) identifying the patient as more likely to have increased rate of progression of the degenerative disease, when at least one risk allele selected from the group consisting of a CFI allele, a CFH allele, a C2 allele, a CFB allele, or a C3 allele is present.SELECTED DRAWING: Figure 7.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 27. Feb. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BRIAN YASPAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-02-27, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
JP2020028293 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003938212 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003938212 | ||
| 003 | DE-627 | ||
| 005 | 20240426161332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240426s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003938212 | ||
| 035 | |a (EPA)JP2020028293 | ||
| 035 | |a (EPA)51422165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BRIAN YASPAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMPOSITIONS AND METHOD FOR TREATING COMPLEMENT-ASSOCIATED CONDITIONS |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-02-27, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26 | ||
| 520 | |a To provide methods for selecting and identifying a patient for treating with a factor D inhibitor.SOLUTION: Provided is a method of predicting progression rate of a degenerative disease in a patient having the degenerative disease, the method comprising: (a) determining the presence of at least one degenerative disease-associated polymorphism in a biological sample obtained from the patient by (i) providing a nucleic acid sample isolated from the biological sample, and (ii) detecting the genotype of the nucleic acid sample for the presence of at least one degenerative disease-associated polymorphism, the polymorphism being a risk allele selected from the group consisting of a CFI allele, a CFH allele, a C2 allele, a CFB allele, or a C3 allele; and (b) identifying the patient as more likely to have increased rate of progression of the degenerative disease, when at least one risk allele selected from the group consisting of a CFI allele, a CFH allele, a C2 allele, a CFB allele, or a C3 allele is present.SELECTED DRAWING: Figure 7 | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ROBERT ROYAL GRAHAM |e verfasserin |4 aut | |
| 700 | 0 | |a AMY DRESSEN |e verfasserin |4 aut | |
| 700 | 0 | |a LI ZHENGRONG |e verfasserin |4 aut | |
| 700 | 0 | |a ERICH STRAUSS |e verfasserin |4 aut | |
| 700 | 0 | |a TEODORICA BUGAWAN |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 27. Feb. |
| 773 | 1 | 8 | |g year:2020 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/51422165/publication/JP2020028293A1?q=JP2020028293 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 27 |c 02 | ||